190 related articles for article (PubMed ID: 25620423)
1. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Yang B; Zhang H; Wang H
J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
[TBL] [Abstract][Full Text] [Related]
2. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
[TBL] [Abstract][Full Text] [Related]
3. Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
Verma S; Goyal S; Kumari A; Singh A; Jamal S; Grover A
PLoS One; 2018; 13(2):e0190942. PubMed ID: 29389942
[TBL] [Abstract][Full Text] [Related]
4. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
Huang Y; Rizzo RC
Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
[TBL] [Abstract][Full Text] [Related]
5. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
[TBL] [Abstract][Full Text] [Related]
6. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
Yu X; Wang T; Lou Y; Li Y
Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
[TBL] [Abstract][Full Text] [Related]
7. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
Ni Z; Wang X; Zhang T; Jin RZ
Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
[TBL] [Abstract][Full Text] [Related]
10. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
11. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
13. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
14. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
[TBL] [Abstract][Full Text] [Related]
15. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
Bello M; Guadarrama-García C; Rodriguez-Fonseca RA
J Comput Aided Mol Des; 2020 Mar; 34(3):293-303. PubMed ID: 31828486
[TBL] [Abstract][Full Text] [Related]
17. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2.
Martiniano B
J Mol Model; 2021 Mar; 27(4):105. PubMed ID: 33686576
[TBL] [Abstract][Full Text] [Related]
18. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
19. Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
Zhao S; Fang W; Pan H; Yang Y; Liang Y; Yang L; Dong X; Zhan J; Wang K; Zhang L
J Thorac Oncol; 2020 Jun; 15(6):962-972. PubMed ID: 32036069
[TBL] [Abstract][Full Text] [Related]
20. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
Ni Z; Zhang TC
J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
